卵巢癌患者生活质量研究进展

doi:10.12280/gjfckx.20210102

摘要/Abstract

摘要：

卵巢癌临床症状相对隐蔽,大多数患者在被确诊时已处于卵巢癌晚期。但随着治疗方案的进步,不少患者可以得到长期生存。因此,对于卵巢癌患者,尤其是晚期复发性卵巢癌患者,改善其生活质量与延长其生存期同等重要。大量研究证实卵巢癌患者在躯体、心理、社会和性等方面受到较为严重的损害,为改善患者生活质量,除需对患者进行贯穿始终的心理调节外,还需根据卵巢癌患者所处的不同时期针对性地进行生活质量的改善。对于初治卵巢癌患者,应审慎选择治疗方案,针对性处理治疗相关不良反应或并发症,督促患者加强体育锻炼;对于无瘤生存期患者,应注重帮助患者恢复工作、社会能力,增强生存信心;对于带瘤生存期患者,应进行症状管理、家庭支持等。

关键词: 卵巢肿瘤, 生活质量, 量表, 无进展生存期, 无瘤生存, 带瘤生存, 复发

Abstract:

Clinical symptoms of ovarian cancer are relatively hidden, and most patients are diagnosed at the advanced stage. However, with the improvement of treatments, many patients can now achieve long-term survival. Therefore, for ovarian cancer patients, especially those with advanced recurrent ovarian cancer, improving their quality of life and prolonging their survival should be equally important. A large number of researches have confirmed that ovarian cancer patients suffer serious damage in physical, psychological, social and sexual status. To improve the patients′ quality of life, besides the psychological adjustment carried out throughout the whole period, physicians should also emphasize on the improvement of quality of life according to different periods of ovarian cancer patients. For patients receiving initial treatments, therapies should be supervised, side effects or complications should be tackled with appropriately, and patients should be urged to strengthen physical exercise; for patients with tumor-free survival, should be paid attention to helping patients restore their work and social ability and enhancing their confidence in survival; for patients with tumor survival, symptom management and family support should be carried out.

Key words: Ovarian neoplasms, Quality of life, Questionnaire, Progression free survival, Disease-free interval, Survival with tumor, Recurrence

林雨璇, 孔为民. 卵巢癌患者生活质量研究进展[J]. 国际妇产科学杂志, 2021, 48(6): 610-614.

LIN Yu-xuan, KONG Wei-min. Research Progress of the Quality of Life of Patients with Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2021, 48(6): 610-614.

参考文献 30

[1]	Berek JS, Kehoe ST, Kumar L, et al. Cancer of the ovary, fallopian tube, and peritoneum[J]. Int J Gynaecol Obstet, 2018,143(Suppl 2):59-78. doi: 10.1002/ijgo.12614. doi: 10.1002/ijgo.12614
[2]	Lutgendorf SK, Shinn E, Carter J, et al. Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach[J]. Gynecol Oncol, 2017,146(1):101-108. doi: 10.1016/j.ygyno.2017.05.008. doi: S0090-8258(17)30846-6 pmid: 28527672
[3]	The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties[J]. Soc Sci Med, 1998,46(12):1569-1585. doi: 10.1016/s0277-9536(98)00009-4. doi: 10.1016/s0277-9536(98)00009-4
[4]	von Gruenigen VE, Huang HQ, Cella D, et al. Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study[J]. Gynecol Oncol, 2018,150(1):119-126. doi: 10.1016/j.ygyno.2018.05.017. doi: S0090-8258(18)30904-1 pmid: 29778506
[5]	Kim SI, Lee Y, Lim MC, et al. Quality of life and sexuality comparison between sexually active ovarian cancer survivors and healthy women[J]. J Gynecol Oncol, 2015,26(2):148-154. doi: 10.3802/jgo.2015.26.2.148. doi: 10.3802/jgo.2015.26.2.148 pmid: 25686396
[6]	Oza AM, Matulonis UA, Malander S, et al. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial[J]. Lancet Oncol, 2018,19(8):1117-1125. doi: 10.1016/S1470-2045(18)30333-4. doi: 10.1016/S1470-2045(18)30333-4
[7]	Koole SN, Kieffer JM, Sikorska K, et al. Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer[J]. Eur J Surg Oncol, 2021,47(1):101-107. doi: 10.1016/j.ejso.2019.05.006. doi: 10.1016/j.ejso.2019.05.006 pmid: 31128948
[8]	Zhou Y, Cartmel B, Gottlieb L, et al. Randomized Trial of Exercise on Quality of Life in Women With Ovarian Cancer: Women′s Activity and Lifestyle Study in Connecticut (WALC)[J]. J Natl Cancer Inst, 2017,109(12):djx072. doi: 10.1093/jnci/djx072. doi: 10.1093/jnci/djx072
[9]	Guy H, Walder L, Fisher M. Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States[J]. Pharmacoeconomics, 2019,37(3):391-405. doi: 10.1007/s40273-018-0745-z. doi: 10.1007/s40273-018-0745-z
[10]	Coleman RL, Spirtos NM, Enserro D, et al. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer[J]. N Engl J Med, 2019,381(20):1929-1939. doi: 10.1056/NEJMoa1902626. doi: 10.1056/NEJMoa1902626
[11]	Wright JD, Hou JY, Burke WM, et al. Utilization and Toxicity of Alternative Delivery Methods of Adjuvant Chemotherapy for Ovarian Cancer[J]. Obstet Gynecol, 2016,127(6):985-991. doi: 10.1097/AOG.0000000000001436. doi: 10.1097/AOG.0000000000001436 pmid: 27159764
[12]	Holliday CM, Morte M, Byrne JM, et al. Experience and Expectations of Ovarian Cancer Patients in Australia[J]. J Oncol, 2018,2018:7863520. doi: 10.1155/2018/7863520. doi: 10.1155/2018/7863520
[13]	Moss JL, Murphy J, Filiaci VL, et al. Disparities in health-related quality of life in women undergoing treatment for advanced ovarian cancer: the role of individual-level and contextual social determinants[J]. Support Care Cancer, 2019,27(2):531-538. doi: 10.1007/s00520-018-4340-9. doi: 10.1007/s00520-018-4340-9
[14]	Medina-Franco H, Mejía-Fernández L. Neoadjuvant chemotherapy and interval debulking surgery for advanced ovarian cancer, an alternative with multiple advantages[J]. Chin Clin Oncol, 2018,7(6):57. doi: 10.21037/cco.2018.06.10. doi: 10.21037/cco.2018.06.10 pmid: 30180749
[15]	Chan JK, Brady MF, Penson RT, et al. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer[J]. N Engl J Med, 2016,374(8):738-748. doi: 10.1056/NEJMoa1505067. doi: 10.1056/NEJMoa1505067
[16]	Kumar S, Long J, Kehoe S, et al. Quality of life outcomes following surgery for advanced ovarian cancer: a systematic review and meta-analysis[J]. Int J Gynecol Cancer, 2019,29(8):1285-1291. doi: 10.1136/ijgc-2018-000125. doi: 10.1136/ijgc-2018-000125
[17]	Holman DA. Fertility Preservation in Gynecologic Cancer[J]. Semin Oncol Nurs, 2019,35(2):202-210. doi: 10.1016/j.soncn.2019.02.007. doi: 10.1016/j.soncn.2019.02.007
[18]	Bauersfeld SP, Kessler CS, Wischnewsky M, et al. The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study[J]. BMC Cancer, 2018,18(1):476. doi: 10.1186/s12885-018-4353-2. doi: 10.1186/s12885-018-4353-2 pmid: 29699509
[19]	Wang R, Sun Q, Wang F, et al. Efficacy and Safety of Chinese Herbal Medicine on Ovarian Cancer After Reduction Surgery and Adjuvant Chemotherapy: A Systematic Review and Meta-Analysis[J]. Front Oncol, 2019,9:730. doi: 10.3389/fonc.2019.00730. doi: 10.3389/fonc.2019.00730
[20]	Morrison V, Spencer LH, Totton N, et al. Trial of Optimal Personalised Care After Treatment-Gynaecological Cancer (TOPCAT-G): A Randomized Feasibility Trial[J]. Int J Gynecol Cancer, 2018,28(2):401-411. doi: 10.1097/IGC.0000000000001179. doi: 10.1097/IGC.0000000000001179 pmid: 29324539
[21]	Rinninella E, Fagotti A, Cintoni M, et al. Nutritional Interventions to Improve Clinical Outcomes in Ovarian Cancer: A Systematic Review of Randomized Controlled Trials[J]. Nutrients, 2019,11(6):1404. doi: 10.3390/nu11061404. doi: 10.3390/nu11061404
[22]	Jones TL, Sandler CX, Spence RR, et al. Physical activity and exercise in women with ovarian cancer: A systematic review[J]. Gynecol Oncol, 2020,158(3):803-811. doi: 10.1016/j.ygyno.2020.06.485. doi: 10.1016/j.ygyno.2020.06.485
[23]	Zhang Q, Li F, Zhang H, et al. Effects of nurse-led home-based exercise & cognitive behavioral therapy on reducing cancer-related fatigue in patients with ovarian cancer during and after chemotherapy: A randomized controlled trial[J]. Int J Nurs Stud, 2018,78:52-60. doi: 10.1016/j.ijnurstu.2017.08.010. doi: S0020-7489(17)30188-8 pmid: 28939343
[24]	Iyer NS, Cartmel B, Friedman L, et al. Lymphedema in ovarian cancer survivors: Assessing diagnostic methods and the effects of physical activity[J]. Cancer, 2018,124(9):1929-1937. doi: 10.1002/cncr.31239. doi: 10.1002/cncr.31239
[25]	Friedlander M, Gebski V, Gibbs E, et al. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial[J]. Lancet Oncol, 2018,19(8):1126-1134. doi: 10.1016/S1470-2045(18)30343-7. doi: S1470-2045(18)30343-7 pmid: 30026002
[26]	Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer[J]. N Engl J Med, 2011,365(26):2473-2483. doi: 10.1056/NEJMoa1104390. doi: 10.1056/NEJMoa1104390
[27]	Bielik J, Bystricky B, Hoffmannova K, et al. Quality of life and ability to work in ovarian cancer patients in Slovakia[J]. Neoplasma, 2020,67(2):389-393. doi: 10.4149/neo_2020_190401N285. doi: 10.4149/neo_2020_190401N285 pmid: 31986888
[28]	Colombo N, Lorusso D, Scollo P. Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future[J]. Int J Gynecol Cancer, 2017,27(6):1134-1140. doi: 10.1097/IGC.0000000000001023. doi: 10.1097/IGC.0000000000001023
[29]	Corrado G, Salutari V, Palluzzi E, et al. Optimizing treatment in recurrent epithelial ovarian cancer[J]. Expert Rev Anticancer Ther, 2017,17(12):1147-1158. doi: 10.1080/14737140.2017.1398088. doi: 10.1080/14737140.2017.1398088
[30]	Iorio GC, Martini S, Arcadipane F, et al. The role of radiotherapy in epithelial ovarian cancer: a literature overview[J]. Med Oncol, 2019,36(7):64. doi: 10.1007/s12032-019-1287-8. doi: 10.1007/s12032-019-1287-8